Clinical Trials Logo

HNSCC clinical trials

View clinical trials related to HNSCC.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04272333 Terminated - HNSCC Clinical Trials

Intratumoral Microdosing of Motolimod in HNSCC

Start date: October 15, 2021
Phase: Early Phase 1
Study type: Interventional

This is a multi-center, single arm, open-label, multi-agent, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of motolimod and motolimod combined with nivolumab when administered intratumorally in microdose quantities via the CIVO device in patients with head and neck squamous cell carcinoma (HNSCC). CIVO stands for comparative in vivo oncology.

NCT ID: NCT03740100 Terminated - HNSCC Clinical Trials

Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

HNSCC
Start date: January 25, 2019
Phase: Phase 2
Study type: Interventional

Preclinical data and limited clinical evidence suggest that Head and Neck Squameous Cell Carcinoma tumors harboring certain mutations may respond well to PI3K/mTOR inhibition (phosphatidylinositol-3-kinase/ mammalian target of rapamycin inhibition). The current study enrolls patients with refractory and / or metastatic Head and Neck Squameous Cell Carcinoma based on the mutational status of their disease to assess the response to treatment with bimiralisib, an orally available pan-PI3K/mTOR inhibitor (phosphatidylinositol-3-kinase/ mammalian target of rapamycin inhibitor).